64384 Federal Register / Vol. 62, No. 234 / Friday, December 5, 1997 / Notices

than January 2, 1998. Requests for

further information may also be

forwarded to this address.

SUPPLEMENTARY INFORMATION: The GSA

is anticipating the preparation of an

Environmental Impact Statement on a

proposal to dispose of excess federal

property in New York, New York. GSA

will serve as the lead agency and

scoping will be conducted consistent

with NEPA regulations and guidelines.

GSA invites interested individuals,

organizations, and Federal, State, and

local agencies to participate in defining

the reasonable alternatives to be

evaluated in the EIS, and in identifying

any significant social, economic, or

environmental issues related to the

alternatives. During scoping, comments

should focus on identifying specific

impacts to be evaluated and suggesting

alternatives that minimize adverse

significant impacts while achieving

similar objectives. Comments may also

identify issues which are not significant

or which have been covered by prior

environmental review. Scoping should

be limited to commenting on

alternatives and the merit of the

proposal rather than indicating

preferences. There will be an

opportunity to comment on preferences

upon completion of the Draft

Environmental Impact Statement (DEIS).

Mailing List: If you wish to be placed

on the project mailing list to receive

future or further information as the EIS

develops, contact Peter A. Sneed at the

address noted above.

Project Purpose, Historical

Background, and Project: On October

16, 1995, the United States Coast Guard

(USCG) announced it would close

Governors Island by the end of summer

1997. The decision to close Governors

Island was made in response to the

Presidential mandate to meet the goals

of the National Performance Review and

the Government Performance and

Results Act. The present organization of

Governors Island will transition to a 60-

person Caretaker Detachment that will

provide security, fire protection and

facility maintenance. Disposal of the

Island is the responsibility of the

General Services Administration. On

August 5, 1997, President Clinton

signed into law, legislation for the sale

of Governors Island. This special

legislation incorporated as part of the

Balanced Budget Act of 1997 directs the

Administrator of General Services

Administration to sell Governors Island

at fair market value. The State and City

of New York have right of first offer to

purchase all or part of the Island at fair

market value.

Alternatives: The EIS will examine

the short and long term impacts on the

natural and built environment. Potential

impact assessment will include but not

be limited to changes in land use and

zoning, changes to air and water quality,

changes to traffic patterns, and impacts

to historic and cultural resources.

The EIS will also examine measures

to mitigate significant unavoidable

adverse impacts resulting from the

proposed action. Concurrent with NEPA

implementation, GSA will also

implement its consultation

responsibilities under Section 106 of the

Natural Historic Preservation Act to

identify potential impacts to existing

historic or cultural resources.

The EIS would consider a no-action

alternative and an action alternative

which would identify several reuse

options. The no-action alternative (nosale) would keep Governors Island in

Federal ownership. The preferred action

alternative is the sale of Governors

Island.

Procedures: The Draft EIS will be

prepared at the completion of and based

upon a scoping report. The Draft EIS

will then be made available for public

and agency review and comment with a

public hearing being held during this

comment period. A Final EIS would be

prepared following conclusion of the

comment period to address issues raised

on the Draft EIS.

Dated: November 28, 1997.

Robert Martin,

Acting Regional Administrator (2A).

[FR Doc. 97–31858 Filed 12–4–97; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Proposed Information Collection

Activity; Comment Request Proposed

Projects

Title: Interim Tribal TANF Data

Report.

OMB No.: New Collection.

Description: This information is being

collected to meet the statutory

requirements of section 411 of the

Social Security Act and section 116 of

the Personal Responsibility and Work

Opportunity Reconciliation Act of 1996.

It consists of desegregated demographic

and program information that will be

used to determine participation rates

and other statutorily required indicators

for the Tribal Temporary Assistance for

Needy Families (Tribal TANF) program.

Respondents: Tribal Governments.

ANNUAL BURDEN ESTIMATES

Instrument Number of respondents

Number of responses per

respondent

Average burden hours per

response

Total burden

hours

TANF Data Report ............................................................................................ 18 4 451 32,472

Estimated Total Annual Burden Hours: 32,472

In compliance with the requirements

of Section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Administration for Children and

Families is soliciting public comment

on the specific aspects of the

information collection described above.

Copies of the proposed collection of

information can be obtained and

comments may be forwarded by writing

to the Administration for Children and

Families, Office of Information Services,

Division of Information Resource

Management Services, 370 L’Enfant

Promenade, SW., Washington, DC

20447, Attn: ACF Reports Clearance

Officer. All requests should be

identified by the title of the information

collection.

The Department specifically requests

comments on: (a) Whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

the quality, utility, and clarity of the

information to be collected; and (d)

ways to minimize the burden of the

collection of information on

respondents, including though the use

of automated collection techniques or

other forms of information technology.

Consideration will be given to
Federal Register / Vol. 62, No. 234 / Friday, December 5, 1997 / Notices 64385

comments and suggestions submitted

within 60 days of this publication.

Dated: November 25, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–31855 Filed 12–4–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0480]

Zenith Goldline Pharmaceuticals;

Withdrawal of Approval of 11

Abbreviated Antibiotic Applications

and 105 Abbreviated New Drug

Applications

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 11 abbreviated antibiotic

applications (AADA’s) and 105

abbreviated new drug applications

(ANDA’s). Zenith Goldline

Pharmaceuticals notified the agency in

writing that the drug products were no

longer marketed and requested that the

approval of the applications be

withdrawn.

EFFECTIVE DATE: January 5, 1998.

FOR FURTHER INFORMATION CONTACT:

Olivia A. Pritzlaff, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–594–

2041.

SUPPLEMENTARY INFORMATION: Zenith

Goldline Pharmaceuticals, 140 Legrand

Ave., Northvale, NJ 07647, has informed

FDA that the drug products listed in the

following table are no longer marketed

and has requested that FDA withdraw

approval of the applications. Zenith

Goldline Pharmaceuticals has also, by

its request, waived its opportunity for a

hearing.

Application No. Drug

AADA 60–072 ............................................................ Penicillin G Potassium Powder, 100,000 units/5 milliliters (mL), 200,000 units/5 mL,

250,000 units/5 mL, 400,000 units/5 mL, 500,000 units/5 mL

AADA 60–073 ............................................................ Penicillin G Potassium Tablets USP, 100,000 units/Tab, 200,000 units/Tab, 250,000 units/

Tab, 400,000 units/Tab, 500,000 units/Tab

AADA 60–104 ............................................................ Chlortetracycline Hydrochloride (HCl) Capsules USP, 250 milligrams (mg)

AADA 60–518 ............................................................ Penicillin V Potassium Tablets USP, 125 mg, 250 mg, 500 mg

AADA 60–519 ............................................................ Penicillin V Potassium Powder, 125 mg/5 mL, 250 mg/5 mL

AADA 60–692 ............................................................ Ampicillin Capsules USP (Trihydrate), 250 mg, 500 mg

AADA 60–765 ............................................................ Ampicillin Capsules USP (Trihydrate), 250 mg, 500 mg

AADA 61–183 ............................................................ Ampicillin for Oral Suspension USP, 125 mg/5 mL, 250 mg/5 mL

AADA 61–468 ............................................................ Tetracycline Syrup, 125 mg/5 mL

AADA 62–237 ............................................................ Erythromycin Estolate Capsules USP, 250 mg

AADA 62–762 ............................................................ Cephradine Capsules USP, 250 mg, 500 mg

ANDA 70–360 ............................................................ Diazepam Tablets USP, 2 mg

ANDA 70–361 ............................................................ Diazepam Tablets USP, 5 mg

ANDA 70–362 ............................................................ Diazepam Tablets USP, 10 mg

ANDA 70–935 ............................................................ Perphenazine and Amitriptyline HCl Tablets USP, 2 mg/10 mg

ANDA 70–936 ............................................................ Perphenazine and Amitriptyline HCl Tablets USP, 2 mg/25 mg

ANDA 70–937 ............................................................ Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/10 mg

ANDA 70–938 ............................................................ Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/25 mg

ANDA 70–939 ............................................................ Perphenazine and Amitriptyline HCl Tablets USP, 4 mg/50 mg

ANDA 71–154 ............................................................ Ibuprofen Tablets USP, 200 mg (Round)

ANDA 71–458 ............................................................ Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/15 mg

ANDA 71–459 ............................................................ Methyldopa and Hydrochlorothiazide Tablets USP, 250 mg/25 mg

ANDA 71–460 ............................................................ Methyldopa and Hydrochlorothiazide Tablets USP, 500 mg/30 mg

ANDA 71–461 ............................................................ Methyldopa and Hydrochlorothiazide Tablets USP, 500 mg/50 mg

ANDA 71–552 ............................................................ Propranolol HCl and Hydrochlorothiazide Tablets USP, 40 mg/25 mg

ANDA 71–553 ............................................................ Propranolol HCl and Hydrochlorothiazide Tablets USP, 80 mg/25 mg

ANDA 72–040 ............................................................ Ibuprofen Tablets USP, 200 mg (Caplet)

ANDA 72–063 ............................................................ Propranolol HCl Tablets USP, 10 mg

ANDA 72–066 ............................................................ Propranolol HCl Tablets USP, 20 mg

ANDA 72–067 ............................................................ Propranolol HCl Tablets USP, 40 mg

ANDA 72–068 ............................................................ Propranolol HCl Tablets USP, 60 mg

ANDA 72–069 ............................................................ Propranolol HCl Tablets USP, 80 mg

ANDA 80–078 ............................................................ Nitrofurantoin Tablets (Microcrystalline) 50 mg, 100 mg

ANDA 80–143 ............................................................ Trisulfapyrimidines Tablets USP

ANDA 80–215 ............................................................ Propylthiouracil Tablets USP, 50 mg

ANDA 80–270 ............................................................ Isoniazid Tablets USP, 100 mg

ANDA 80–283 ............................................................ Prednisone Tablets USP, 5 mg

ANDA 80–378 ............................................................ Prednisolone Tablets USP, 5 mg

ANDA 80–630 ............................................................ Cortisone Acetate Tablets USP, 25 mg

ANDA 80–735 ............................................................ Dimenhydrinate Tablets USP, 50 mg

ANDA 80–762 ............................................................ Diphenhydramine HCl Capsules USP, 25 mg, 50 mg

ANDA 80–779 ............................................................ Chlorphenirarnine Maleate Tablets USP, 4 mg

ANDA 83–035 ............................................................ Vitamin A Capsules USP, 50,000 units

ANDA 83–077 ............................................................ Propoxyphene Compound Capsules